Close Menu

NEW YORK — The US Food and Drug Administration on Friday granted Emergency Use Authorization to GenScript Biotech's cPass SARS-CoV-2 Neutralization Antibody Detection Kit.

It is the first SARS-CoV-2 neutralizing antibody test to receive EUA, the FDA said.

The blocking ELISA detection assay, which is designed to mimic the virus neutralization process, detects total neutralizing antibodies to SARS-CoV-2 in human serum and plasma. Results are provided in around one hour.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.